Stance of MRD in Non‑Hodgkin’s Lymphoma and its upsurge in the novel era of cell‑free DNA

• S. Garg ^[1] ; A. Kumar ^[2] ; R. Gupta ^[1]
  1. [1] Laboratory Oncology Unit, Dr B.R.A.IRCH, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029, India
  2. [2] Medical Oncology Department, National Cancer Institute, AIIMS, Jhajjar, Haryana, India
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 11, 2021, págs. 2206-2219
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Cancer genomics has evolved over the years from understanding the pathogenesis of cancer to screening the future possibili- ties of cancer occurrence. Understanding the genetic profile of tumors holds a prognostic as well as a predictive value in this era of therapeutic surveillance, molecular remission, and precision medicine. Identifying molecular markers in tumors is the current standard of approach, and requires an efficient combination of an accessible sample type and a profoundly sensi- tive technique. Liquid biopsy or cell-free DNA has evolved as a novel sample type with promising results in recent years.

    Although cell-free DNA has significant role in various cancer types, this review focuses on its application in Non-Hodgkin’s Lymphoma. Beginning with the current concept and clinical relevance of minimal residual disease in Non-Hodgkin’s lym- phoma, we discuss the literature on circulating DNA and its evolving application in the realm of cutting-edge technology.